Anti-inflammatory properties of exenatide in human pancreatic islets

S. R. Cechin, I. Pérez-Álvarez, E. Fenjves, Ruth Molano, A. Pileggi, P. O. Berggren, Camillo Ricordi, Ricardo Pastori

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Exenatide is an analog of the incretin hormone glucagon-like peptide (GLP-1) that is used for the treatment of T2D for their metabolic effects. In addition to its insulinotropic effects, exenatide increases functional islet mass and improves their survival. Improved outcomes have been reported in recent clinical islet transplantation trials for the treatment of type 1 diabetes. The purpose of this study was to investigate whether exenatide has anti-inflammatory properties in human islets. Exenatide treatment improved islet function, significantly reduced content of inflammation-related molecules (tissue factor, IFN-γ, IL-17, IL-1β, and IL-2) and caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt in vitro. Immunostaining showed expression of GLP-1R in β-cells but not in α-cells. IL-1β colocalized with GLP- 1R in β-cells. Induction of serine proteinase inhibitor 9 (PI-9) was detected after exposure of human islets to exenatide in vitro and after transplantation into immunodeficient mice. GLP-1 induced PI-9 expression in vitro but to a lower extent than exenatide. This effect was partially blocked by the antagonist exendin-9 in vitro. As assessed by immunostaining PI-9 is mostly expressed in β-cells but not in α-cells. In conclusion, we describe anti-inflammatory and cytoprotective properties of exenatide in human islets. Exenatide-mediated PI-9 expression, the only known granzyme B inhibitor, unveils potential immunoregulatory properties.

Original languageEnglish (US)
Pages (from-to)633-648
Number of pages16
JournalCell Transplantation
Volume21
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Islets of Langerhans
Anti-Inflammatory Agents
Glucagon-Like Peptide 1
Phosphorylation
Peptide Hydrolases
Hormones
Medical problems
Interleukin-1
Peptides
Chemical activation
Tissue
Incretins
Granzymes
Islets of Langerhans Transplantation
Molecules
Serine Proteinase Inhibitors
Interleukin-17
exenatide
Interleukin-3
Thromboplastin

Keywords

  • Cytokines
  • Exenatide
  • Glucagon-like peptide-1
  • Human pancreatic islets
  • Inflammation
  • Islet transplantation
  • Nude mice
  • Proteinase inhibitor 9 (PI-9)

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R., Pileggi, A., Berggren, P. O., ... Pastori, R. (2012). Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplantation, 21(4), 633-648. https://doi.org/10.3727/096368911X576027

Anti-inflammatory properties of exenatide in human pancreatic islets. / Cechin, S. R.; Pérez-Álvarez, I.; Fenjves, E.; Molano, Ruth; Pileggi, A.; Berggren, P. O.; Ricordi, Camillo; Pastori, Ricardo.

In: Cell Transplantation, Vol. 21, No. 4, 2012, p. 633-648.

Research output: Contribution to journalArticle

Cechin, SR, Pérez-Álvarez, I, Fenjves, E, Molano, R, Pileggi, A, Berggren, PO, Ricordi, C & Pastori, R 2012, 'Anti-inflammatory properties of exenatide in human pancreatic islets', Cell Transplantation, vol. 21, no. 4, pp. 633-648. https://doi.org/10.3727/096368911X576027
Cechin SR, Pérez-Álvarez I, Fenjves E, Molano R, Pileggi A, Berggren PO et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplantation. 2012;21(4):633-648. https://doi.org/10.3727/096368911X576027
Cechin, S. R. ; Pérez-Álvarez, I. ; Fenjves, E. ; Molano, Ruth ; Pileggi, A. ; Berggren, P. O. ; Ricordi, Camillo ; Pastori, Ricardo. / Anti-inflammatory properties of exenatide in human pancreatic islets. In: Cell Transplantation. 2012 ; Vol. 21, No. 4. pp. 633-648.
@article{7b3965a70bf94954b99a0a80436cbe51,
title = "Anti-inflammatory properties of exenatide in human pancreatic islets",
abstract = "Exenatide is an analog of the incretin hormone glucagon-like peptide (GLP-1) that is used for the treatment of T2D for their metabolic effects. In addition to its insulinotropic effects, exenatide increases functional islet mass and improves their survival. Improved outcomes have been reported in recent clinical islet transplantation trials for the treatment of type 1 diabetes. The purpose of this study was to investigate whether exenatide has anti-inflammatory properties in human islets. Exenatide treatment improved islet function, significantly reduced content of inflammation-related molecules (tissue factor, IFN-γ, IL-17, IL-1β, and IL-2) and caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt in vitro. Immunostaining showed expression of GLP-1R in β-cells but not in α-cells. IL-1β colocalized with GLP- 1R in β-cells. Induction of serine proteinase inhibitor 9 (PI-9) was detected after exposure of human islets to exenatide in vitro and after transplantation into immunodeficient mice. GLP-1 induced PI-9 expression in vitro but to a lower extent than exenatide. This effect was partially blocked by the antagonist exendin-9 in vitro. As assessed by immunostaining PI-9 is mostly expressed in β-cells but not in α-cells. In conclusion, we describe anti-inflammatory and cytoprotective properties of exenatide in human islets. Exenatide-mediated PI-9 expression, the only known granzyme B inhibitor, unveils potential immunoregulatory properties.",
keywords = "Cytokines, Exenatide, Glucagon-like peptide-1, Human pancreatic islets, Inflammation, Islet transplantation, Nude mice, Proteinase inhibitor 9 (PI-9)",
author = "Cechin, {S. R.} and I. P{\'e}rez-{\'A}lvarez and E. Fenjves and Ruth Molano and A. Pileggi and Berggren, {P. O.} and Camillo Ricordi and Ricardo Pastori",
year = "2012",
doi = "10.3727/096368911X576027",
language = "English (US)",
volume = "21",
pages = "633--648",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "4",

}

TY - JOUR

T1 - Anti-inflammatory properties of exenatide in human pancreatic islets

AU - Cechin, S. R.

AU - Pérez-Álvarez, I.

AU - Fenjves, E.

AU - Molano, Ruth

AU - Pileggi, A.

AU - Berggren, P. O.

AU - Ricordi, Camillo

AU - Pastori, Ricardo

PY - 2012

Y1 - 2012

N2 - Exenatide is an analog of the incretin hormone glucagon-like peptide (GLP-1) that is used for the treatment of T2D for their metabolic effects. In addition to its insulinotropic effects, exenatide increases functional islet mass and improves their survival. Improved outcomes have been reported in recent clinical islet transplantation trials for the treatment of type 1 diabetes. The purpose of this study was to investigate whether exenatide has anti-inflammatory properties in human islets. Exenatide treatment improved islet function, significantly reduced content of inflammation-related molecules (tissue factor, IFN-γ, IL-17, IL-1β, and IL-2) and caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt in vitro. Immunostaining showed expression of GLP-1R in β-cells but not in α-cells. IL-1β colocalized with GLP- 1R in β-cells. Induction of serine proteinase inhibitor 9 (PI-9) was detected after exposure of human islets to exenatide in vitro and after transplantation into immunodeficient mice. GLP-1 induced PI-9 expression in vitro but to a lower extent than exenatide. This effect was partially blocked by the antagonist exendin-9 in vitro. As assessed by immunostaining PI-9 is mostly expressed in β-cells but not in α-cells. In conclusion, we describe anti-inflammatory and cytoprotective properties of exenatide in human islets. Exenatide-mediated PI-9 expression, the only known granzyme B inhibitor, unveils potential immunoregulatory properties.

AB - Exenatide is an analog of the incretin hormone glucagon-like peptide (GLP-1) that is used for the treatment of T2D for their metabolic effects. In addition to its insulinotropic effects, exenatide increases functional islet mass and improves their survival. Improved outcomes have been reported in recent clinical islet transplantation trials for the treatment of type 1 diabetes. The purpose of this study was to investigate whether exenatide has anti-inflammatory properties in human islets. Exenatide treatment improved islet function, significantly reduced content of inflammation-related molecules (tissue factor, IFN-γ, IL-17, IL-1β, and IL-2) and caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt in vitro. Immunostaining showed expression of GLP-1R in β-cells but not in α-cells. IL-1β colocalized with GLP- 1R in β-cells. Induction of serine proteinase inhibitor 9 (PI-9) was detected after exposure of human islets to exenatide in vitro and after transplantation into immunodeficient mice. GLP-1 induced PI-9 expression in vitro but to a lower extent than exenatide. This effect was partially blocked by the antagonist exendin-9 in vitro. As assessed by immunostaining PI-9 is mostly expressed in β-cells but not in α-cells. In conclusion, we describe anti-inflammatory and cytoprotective properties of exenatide in human islets. Exenatide-mediated PI-9 expression, the only known granzyme B inhibitor, unveils potential immunoregulatory properties.

KW - Cytokines

KW - Exenatide

KW - Glucagon-like peptide-1

KW - Human pancreatic islets

KW - Inflammation

KW - Islet transplantation

KW - Nude mice

KW - Proteinase inhibitor 9 (PI-9)

UR - http://www.scopus.com/inward/record.url?scp=84930476726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930476726&partnerID=8YFLogxK

U2 - 10.3727/096368911X576027

DO - 10.3727/096368911X576027

M3 - Article

VL - 21

SP - 633

EP - 648

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 4

ER -